1 *Kelch13* and *MDR1* Polymorphisms, and Drug Effectiveness at Day 3 after
2 Dihydroartemisinin-Piperaquine Treatment for *Plasmodium falciparum* Malaria
3 on Bioko Island, Equatorial Guinea: 2014-2017

4 Yu-Zhong Zheng^{1#}, Jiang-Tao Chen^{2#}, Xue-Yan Liang^{1,3}, Carlos Salas Ehapo⁴, Urbano
5 Monsuy Eyi⁴, Hui-Ying Huang^{1,3}, Wei-Zhong Chen³, Li-Yun Lin¹, Dong-De Xie²,
6 Yu-Ling Wang², Guo-Wei Chen², Xiang-Zhi Liu³, Guang-Cai Zha¹, Huan-Tong Mo³,
7 Xin-Yao Chen³, Jian Li⁵, Ting-Ting Jiang⁵, Min Lin¹

8 ¹School of Food Engineering and Biotechnology, Hanshan Normal University,
9 Chaozhou, Guangdong Province, People's Republic of China;

10 ²The Chinese Medical Aid Team to the Republic of Equatorial Guinea, Guangzhou,
11 Guangdong Province, People's Republic of China; Department of Medical Laboratory,
12 Huizhou Central Hospital, Huizhou, Guangdong Province, People's Republic of
13 China;

14 ³Department of Medical Laboratory, Chaozhou People's Hospital Affiliated to
15 Shantou University Medical College, Chaozhou, Guangdong Province, People's
16 Republic of China;

17 ⁴Department of Medical Laboratory, Malabo Regional Hospital, Malabo, Equatorial
18 Guinea;

19 ⁵Department of Human Parasitology, School of Basic Medical Sciences; Department
20 of Infectious Diseases, Renmin Hospital, Hubei University of Medicine, Shiyan,
21 People's Republic of China

22 [#]These authors contributed equally to this work.

23 E-mail address: konfutea@hotmail.com

ABSTRACT

Artemisinin (ART) combination therapies were introduced on malaria endemic Bioko Island in 2004 through Bioko Island Malaria Control Project. Recently, ART-resistant *Plasmodium falciparum* strain with *Kelch13* (K13) propeller M579I mutation originating from Equatorial Guinea was observed as an increased parasite clearance time on day 3 after dihydroartemisinin-Piperaquine (DHA-PIP) treatment (D3 positivity). Here, we surveyed DHA-PIP effectiveness and molecular markers of drug resistance at D3 after DHA-PIP treatment on Bioko Island from 2014 to 2017. Among the 371 uncomplicated *P. falciparum* patients, 86.3% (320/471) were successfully followed up at D3. 5.9% (19/320) of patients showed D3 positivity. K13 and MDR1 gene were successfully sequenced from 46 patients collected at D0 (baseline population) and 19 D3-positivity patients. Five non-synonymous K13 mutations (H136N; K189N; K248N; K326E; K332N) were found. There was no statistical difference in the frequency of these K13 mutations between baseline population and D3-positivity samples ($p>0.05$). Additionally, none of the K13 propeller polymorphisms known to be involved in ART-resistance in Asia or Africa were detected. For MDR1 gene, 38.5% (25/65) carried N86Y mutation; 73.8% (48/65) the Y184F mutation. Parasites surviving DHA-PIP at D3 post-treatment were significantly more likely than the baseline population to carry the N86Y ($p < 0.05$). These results suggest that K13 is not the best predictive molecular marker for ART resistance in Africa. More isolates from cases with delayed parasite clearance after DHA-PIP treatment indicated that *in vitro* and *in vivo* monitoring for ART derivatives and ACT partner drugs should be regularly performed on Bioko Island, Equatorial Guinea.

KEYWORDS: Dihydroartemisinin-Piperaquine(DHA-PIP), *Plasmodium falciparum*, Bioko Island, drug resistance

INTRODUCTION

Malaria is one of the most important tropical parasitic diseases with an estimated 219 million cases and 435,000 deaths in 2017 (1). The emergence of *Plasmodium falciparum* resistance to anti-malarial drugs has been threatening the world's malaria control and elimination efforts (2,3). Currently, World Health Organization (WHO) recommends artemisinin (ART) combination therapies (ACTs) as first-line treatment for uncomplicated *P. falciparum* malaria many endemic countries worldwide, and shown to have greatly contributed to the reduction in malaria morbidity and mortality (4). In Recent years, strong evidences supported that malaria parasites resistant to ARTs have emerged and are spreading in certain parts of Southeast Asia, and raises concerns that resistance may emerge and become widespread in high-burden settings, such as Africa (5,6). Untill now, the efficacy of ACTs remains high in Africa. However, evidence based on classical microscopic parasite detection suggests that a proportion of ACT-treated children in Kenya do not completely clear *P. falciparum* parasitemia (7). Additionally, recently Lu et al. observed (2017) an ART-resistant *P. falciparum* strain originating from Equatorial Guinea, Africa (6).

Characterization of ART-resistant parasite is primarily discriminated by nucleotide polymorphisms in the propeller domain of the *P. falciparum* kelch13 gene (K13, *Pf3D7_1343700*) (8). In Southeast Asia, K13 propeller polymorphism, such as Y493H, R539T, I543T and C580Y, is considered a reliable molecular marker for ART-resistant parasites, which showed increased survival rates in ring-stage survival assays (RSAs) and delayed parasite clearance in ACT-treated patients (5,8,9). Parasite clearance can be quantified either by the detection of parasites in patients on day 3 (i.e., “D3 positivity”) (10). The proportion of patients who are still parasitaemic on D3 after treatment with artesunate or ACT is currently an indicator for routine monitoring to identify suspected ART resistance (10).

Bioko Island, Equatorial Guinea, with historically high malaria transmission, has been subject to extensive interventions including intensive vector control, improved case management, intermittent preventative treatments (IPT) and behavioural change interventions since 2004 through the Bioko Island Malaria Control Project (BIMCP)

(11). Through BIMCP, including the introduction of indoor residual spraying (IRS) and distribution of insecticide-treated nets (ITNs) to all households on Bioko Island, first-line artemisinin containing antimalarials (ACAs) free of charge, the parasite prevalence reduced from 43.3 to 10.5% between 2004 and 2016 (11). ACAs used in Equatorial Guinea have included artesunate plus sulfadoxine-pyrimethamine, artesunate plus amodiaquine and dihydroartemisinin-piperaquine (DHA-PIP) (12). Although ACAs are available and free, many people still sought their medicines at a private pharmacy rather than received treatment from the public health services (12). Additionally, falsified ACAs have been reported on Bioko Island, with the prevalence ranging between 6.1% and 16.1%, depending on the sampling method used (12). All of this increased the risk of ART-resistance in the region.

Our previous study showed that the absence of mutations in the propeller region of K13 in parasites from Bioko Island during 2013-2014 (13). The objectives of this study were to investigate the *K13* and *MDR1* polymorphisms, and drug effectiveness at Day 3 after DHA-PIP Treatment for *P. falciparum* Malaria on Bioko Island from 2014 to 2017.

RESULTS

General characters

From January 2014 to December 2017, we enrolled 471 patients with *P. falciparum* uncomplicated malaria from Bioko, Equatorial Guinea. The median (interquartile range [IQR]) age of patients was 26 years (18 to 38.5), and 36.9% of them were women. The median (IQR) parasite density was 3300 parasites/ μ l (1840 to 7000). Among the 471 enrolled patients, 86.3% (320/471) were successfully followed up on D3. The median (IQR) age of these patients was 26 years (17 to 37), and 40.0% of them were women. The median (IQR) parasite density was 3400 parasites/ μ l (1810 to 7940).

Among the 320 patients evaluated on D3, 5.9% (19/320) showed D3 positivity by microscopy, which was also confirmed and identified the *Plasmodium* species by PCR-HRM (14,15). These 19 patients had D0 and D3 parasite densities of 900 to 8000 and 40 to 2120 parasites/ μ l, respectively.

Analysis of *K13* propeller gene

K13 propeller gene was successfully amplified and sequenced from 65 patients including baseline population (46 patients randomly selected from the 301 patients without ART-resistance, collected at D0) and 19 D3-positivity patients. Five non-synonymous mutations (H136N, CAT>AAT; K189N, AAG>AAC; K248N, AAG>AAT; K326E, AAA>GAA and K332N, AAA>AAC) were detected from the two groups (Table 1). However, none of the polymorphisms known to be involved in ART-resistance in Asia (8) or Africa (M579I) (6) were detected. There was no statistical difference in the frequency of these non-synonymous mutations between baseline population and D3 samples ($p>0.05$).

The *K* value for the whole gene of the 65 samples was 0.763. The highest nucleotide differences was found in the *Plasmodium*-specific region (codons 1-440) ($K=0.732$) while the lowest was found in the propeller domain (codons 441-726) ($K=0.030$). The overall haplotype diversity (H_d) and nucleotide diversity (π) in this gene were estimated to be 0.631 ± 0.037 and 0.00039, respectively. Tajima's D test, Fu and Li's tests were also performed to analyze the natural selection in the Bioko *P.*

falciparum K13 gene. The evidence of selection occurring on the K13 gene was not very conclusive as Tajima's D was negative (-1.590, $p>0.05$), but the Fu & Li's D&F was positive (D: -3.546, $p<0.05$; F -3.415, $p<0.05$) for the whole gene.

Analysis of *MDR1* gene

All samples were successfully amplified and sequenced for MDR1 codons 86, 184, 1034, 1042, and 1246. Of the 65 samples, 38.5% (25/65) carried N86Y (AAC>TAT) mutation; 73.8% (48/65) the Y184F (TAT>TTT) mutation. No mutation was found at 1034, 1042 and 1246. As shown in Table 1, the proportion of patients carrying the mutation N86Y and Y184F in the baseline population was higher than that on D3. However, there was only a statistical difference in the proportion of N86Y mutation between the baseline population and D3-positive samples ($p < 0.05$).

DISCUSSION

There is a perennially high rate of malaria transmission throughout Equatorial Guinea, and DHA-PIP is currently commonly used for treatment. To the best of our knowledge, this is the first report to evaluate the effectiveness of routine DHA-PIP treatment for uncomplicated malaria, and described the drug-resistance genetic polymorphisms in D3-positivity *P. falciparum* isolates after DHA-PIP treatment in Equatorial Guinea. Our results showed that DHA-PIP drugs were efficacious in treating uncomplicated *P. falciparum* malaria in the region. This high cure rate of DHA-PIP for Bioko *P. falciparum* supports earlier findings from and across Africa (16-21). This ACT medicine is being increasingly recommended in malaria endemic countries as second-line treatment for *falciparum* malaria and also used for mass drug administration in special situations (21). However, it was found 5.9% (19/320) patients with D3 positivity, suggesting the possibility that a subset of parasites is becoming less susceptible to ART through mutation in some gene, that some individuals have relatively poor parasite-clearing immune responses, or that some patients were not self-administering their remaining doses of DHA-PIP. Based on these results, intensive surveillance of ART derivatives and ACT partner drugs must be conducted regularly on Bioko Island.

Due to the condition limitation, this study was not determining the *in vitro* susceptibility to ART derivatives using the ring survival test. Indeed, clinical resistance to ART is manifested by an increase in the ring-stage survival rate after contact with ART (5,8,9). In Southeast Asia, an increase in the ring-stage survival rate was also associated with the detection of K13 mutations including F446I, N458Y, Y493H, R539T, I543T, R561H and C580Y (5,8,9). In the present study, lower nucleotide differences ($K=0.030$) in the propeller domain of K13 gene were observed in the Bioko *P. falciparum* parasites collected during 2014 to 2017. No patients carried the mutations associated with ART-resistance in Asia (8). Notably, the K13 propeller mutation (M579I) associated with ART-resistance originating from Equatorial Guinea (6) was not observed on Bioko Island. These results are consistent with our previous study on the island in 2012-2014 (13), which revealed a limited

number of genetic polymorphisms in the K13-propeller region. In addition, Bioko had the higher prevalence of isolates with mutant codons in the *Plasmodium*-specific region (46.2%, 30/65). The most frequently mutation was one non-synonymous mutation at proximal end (upstream region) K189N (83.3%, 25/30). Although the K189N mutation was observed at a comparatively higher frequency in the parasitic isolates, no correlation with clinical phenotype was observed among them (OR: 1.06, 95% CI 0.35-3.20, $p=0.863$) (Table 1). Previous study (22,23) revealed that the infections carried K189T/N had a median $PC_{1/2}$ of 2.1 h (range 0.8-7.1) similar to that of infections with wild type parasites; 2.2 h (range 0.7-6.3). In Africa, significantly prolonged clearance has not yet been observed and the presently restricted variation in parasite clearance cannot be explained by K13 polymorphisms (23). All of these suggest that SNPs at K13 is not the best predictive molecular marker for ART-resistance among African patients. More isolates from cases of clinical failure or with delayed parasite clearance after treatment with ART derivatives are necessary to identify new molecular markers.

In our study, the frequency of N86Y mutation was significant higher in the patients prior to treatment (D0) than that on D3-positive patients ($p<0.05$). According to previous reports (24,25), the parasites containing the MDR1 86Y allele showed significantly higher piperazine IC₅₀s compared with those containing the MDR1 N86 allele. Multivariate analysis also revealed that MDR1 86Y allele was an associated factor of reduced piperazine sensitivity. The important role of mutations in the MDR1 gene on *in vitro* piperazine sensitivity has been confirmed by a recent study using genetically modified *P. falciparum* lines (26). Since the implementation of fixed-dose ACT through BIMCP, DHA-PIP would be started on Bioko Island; parasites with reduced piperazine sensitivity might be selected in such areas. Thus, *in vitro* and *in vivo* monitoring should be regularly performed in the region.

In conclusion, these results suggest that K13 is not the best predictive molecular marker for ART-resistance in Africa. Although DHA-PIP remains efficacious in the study region and those ART-resistance mutations are not found, ACT may pose positive selection on the parasites. In additionally, the rate of transmission and the

200 diversity of vector species on Bioko Island may also increase selection pressure on
201 parasite strains (14). More isolates from cases with delayed parasite clearance after
202 DHA-PIP treatment indicated that *in vitro* and *in vivo* monitoring for ART derivatives
203 and ACT partner drugs should be regularly performed on Bioko Island, Equatorial
204 Guinea.
205

MATERIALS AND METHODS

Study area. The study was carried out in the Malabo Regional Hospital and the clinic of the Chinese medical aid team to the Republic of Equatorial Guinea on Bioko Island. Ethical approval was obtained from the Ethics Committee of Malabo Regional Hospital. Bioko is an island 32 km off the west coast of Africa, and the northernmost part of Equatorial Guinea. It's population, of approximately 334, 463 (2015 census, of which approximately 90% live in Malabo, the capital city) are at risk of malaria year-round (14). Before the launch of the BIMCP in 2004, entomological inoculation rates (EIR) on the island were in excess of 750 infectious bites per person per year (14).

***Plasmodium falciparum* isolates.** A total of 471 patients with uncomplicated malaria were collected and analysed between January 2014 and December 2017. Included patients were aged between 12 and 67 years, were residents on Bioko Island. Malaria patients were classified into uncomplicated malaria states according to the WHO criteria, which were defined as positive smear for *P. falciparum* and presence of fever ($\geq 37.5^{\circ}\text{C}$) (27). Consent was obtained from all participating subjects or their parents. Laboratory screening for malaria was done using an Immunochromatographic Diagnostic Test (ICT Malaria Combo Cassette Test) and confirmed using microscopic examination of blood smears (13,14). Extra blood drops were collected for a malaria smear and onto Whatman 903® filter paper (GE Healthcare, Pittsburgh, USA). The *Plasmodium* species were identified by a real-time PCR followed by high-resolution melting (PCR-HRM) as our previous reports (14,15). Patients positive for *P. falciparum* were treated with DHA-PIP according to the national treatment guidelines. The first dose was taken under the supervision of and observed by the pharmacy owner, who also provided the patients with clear explanation for consumption of the remaining two doses at home. All patients were asked again to confirm completion of DHA-PIP doses when they returned on D3 for clinical and parasitological follow-up.

PCR amplification of K1 and MDR1 gene. Genomic DNA was extracted from dried filter bloodspots (DBS) with Genomic DNA Extraction Kit for Dry Blood Spot [(No. DP334) TIANGENE Biotech (Beijing) CO., Ltd], and following the

manufacturer's protocol.

We developed a new PCR method to amplify the entire K13 gene (Pf3D7_1343700) (Fig. 1A). The primary PCR primers (K13_PCR_F and K13_PCR_R) amplified the expected 2,097 bp product under the following conditions: 95°C for 3 min; 30 cycles of 98°C for 10 s, 58°C for 10s, 72°C for 2 min; and final extension at 72°C for 10 min; The nested PCR primers (K13_N1_F and K13_N2_R) amplified the expected 2,027bp product under the following conditions: 95°C for 3 min; 35 cycles of 98°C for 10 s, 55°C for 5s, 72°C for 2 min; and final extension at 72°C for 10 min. TaKaRa Taq™ HS Perfect Mix (TaKaRaAa, Carlsbad, CA) was used as the master mix and was supplemented with a 0.2 µM concentration of each primer. Final volumes for primary and nested PCRs were 25 µl (12.5 µl master mix plus 1 µl DNA template) and 50 µl (25 master mix plus 1 µl primary PCR product), respectively.

In order to capture MDR1 SNPs at codons 86, 130, 184, 1034, 1042, 1109, and 1246, a nest PCR were performed to amplify 2 shorter fragments (Fig. 1B) as our previous reports (28,29).

Sequence polymorphism analysis. All PCR products were analyzed using 1.0% agar gel electrophoresis and DNA sequencing using an ABI 3730XL automated sequencer (PE Biosystems, CT, USA). The nucleotide and deduced amino acid sequences of K13 and MDR1 were analysed using EditSeq and SeqMan in the DNASTAR package (DNASTAR, Madison, WI, USA). The K13 and MDR1 sequences of the laboratory-adapted *P. falciparum* strain 3D7 (XM_001351086) was included in the alignment for comparison as a reference sequence. In K13 gene, the values of segregating sites (S), the average number of pair-wise nucleotide differences (K), haplotype diversity (Hd), and nucleotide diversity (π) were calculated using DnaSP version 5.10.00. The π was also calculated on a sliding window plot of 10 bases with a step size of 5 bp in order to estimate the stepwise diversity across the sequences. Tajima's D test, Fu and Li's D and F statistics analysis were performed using DnaSP package ver. 5.10.00 in order to evaluate the neutral theory of natural selection. The recombination parameter (R), which included the effective population size and probability of recombination between adjacent nucleotides per generation,

266 and the minimum number of recombination events (R_m) were analysed using DnaSP
267 version 5.10.00. The frequency data was analyzed using SPSS 17.0 (SPSS Inc.,
268 Chicago, IL). The p -value < 0.05 was considered statistically significant.
269

Contributions

ML, JTC and YZZ designed the study. CSE, UME, DDX, YLW, GWC collected the samples, entered the data and validated microscopy. XYL, HYH and YZZ analyzed and interpreted the data. XZL, GCZ, HTM, XYC, JL, TTJ, WZC and LYL conducted the laboratory work (*P. falciparum* PCR and analysis of molecular markers). ML and YZZ wrote the paper. All authors critically reviewed the paper and approved the final version of the paper for submission.

Declaration of Interest

The Authors report no conflicts of interest.

Acknowledgments

The authors thank the Department of Health of Guangdong Province and Department of Aid to Foreign Countries of Ministry of Commerce of People's Republic of China for their help. The authors also thank Santiago-m Monte-Nguba for his technical help during the samples collection and diagnosis. This work was partially supported by Natural Science Foundation of Guangdong Province (Grant No. 2016A03031311 to Jiang-Tao Chen; 2018A030307074 to Yu-Zhong Zheng) and Guangdong Science and Technology Project (Grant No. 2016A030303064 to Guang-Cai Zha).

Reference

1. World Health Organization. 2018. World malaria report 2018. World Health Organization. <https://www.who.int/malaria/publications/world-malaria-report-2018/report/en/>.
2. Ngassa Mbenda HG, Das A. 2016. Analysis of genetic diversity in the chloroquine-resistant gene Pfcrt in field *Plasmodium falciparum* isolates from five regions of the southern Cameroon. Infect Genet Evol 44:450–458. <https://doi.org/10.1016/j.meegid.2016.07.003>.
3. Madamet M, Kounta MB, Wade KA, Lo G, Diawara S, Fall M, Bercion R, Nakoulima A, Fall KB, Benoit N, Gueye MW, Fall B, Diatta B, Pradines B. 2017. Absence of association between polymorphisms in the K13 gene and the presence of *Plasmodium falciparum* parasites at day 3 after treatment with artemisinin derivatives in Senegal. Int J Antimicrob Agents 49:754–756. <https://doi.org/10.1016/j.ijantimicag.2017.01.032>.
4. Whegang Youdom S, Chiabi A, Basco LK. 2019. Monitoring the Efficacy and Safety of Artemisinin-Based Combination Therapies: A Review and Network Meta-analysis of Antimalarial Therapeutic Efficacy Trials in Cameroon. Drugs R D 19:1–14. <https://link.springer.com/article/10.1007%2Fs40268-018-0259-3>.
5. von Seidlein L, Peto TJ, Landier J, Nguyen TN, Tripura R, Phommason K, Pongvongsa T, Lwin KM, Keereecharoen L, Kajeechiwa L, Thwin MM, Parker DM, Wiladphaingern J, Nosten S, Proux S, Corbel V, Tuong-Vy N, Phuc-Nhi TL, Son DH, Huong-Thu PN, Tuyen NTK, Tien NT, Dong LT, Hue DV, Quang HH, Nguon C, Davoeung C, Rekol H, Adhikari B, Henriques G, Phongmany P, Suangkanarat P, Jeeyapant A, Vihokhern B, van der Pluijm RW, Lubell Y, White LJ, Aguas R, Promnarate C, Sirithiranont P, Malleret B, Rénia L, Onsjö C, Chan XH, Chalk J, Miotto O, Patumrat K, Chotivanich K, Hanboonkunupakarn B, Jittmala P, Kaehler N, Cheah PY, Pell C, Dhorda M, Imwong M, Snounou G, Mukaka M, Peerawaranun P, Lee SJ, Simpson JA, Pukrittayakamee S, Singhasivanon P, Grobusch MP, Cobelens F, Smithuis F, Newton PN, Thwaites GE, Day NPJ, Mayxay M, Hien TT, Nosten FH, Dondorp AM, White NJ. 2014. Spread of artemisinin resistance in *Plasmodium falciparum* malaria. N Engl J Med 371:411–423. <https://www.nejm.org/doi/10.1056/NEJMoa1314981>.
6. Lu F, Culleton R, Zhang M, Ramaprasad A, von Seidlein L, Zhou H, Zhu G, Tang JI, Liu Y, Wang W, Cao Y, Xu S, Gu Y, Li J, Zhang C, Gao Q, Menard D, Pain A,

- Yang H, Zhang Q, Cao J. 2017. Emergence of Indigenous Artemisinin-Resistant *Plasmodium falciparum* in Africa. N Engl J Med 376:991–993. <https://www.nejm.org/doi/10.1056/NEJMc1612765>.
7. Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S, Frühauf H, Schaub B, Pfeil J, Peshu J, Hanpithakpong W, Rippert A, Juma E, Tsofa B, Mosobo M, Lowe B, Osier F, Fegan G, Lindegårdh N, Nzila A, Peshu N, Mackinnon M, Marsh K. 2011. Declining responsiveness of *Plasmodium falciparum* infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One 6:e26005. <https://doi.org/10.1371/journal.pone.0026005>.
8. Ménard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, et al. 2016. A Worldwide Map of *Plasmodium falciparum* K13-Propeller Polymorphisms. N Engl J Med 374:2453–2464. <https://www.nejm.org/doi/10.1056/NEJMoa1513137>.
9. Montenegro M, Neal AT, Posada M, De Las Salas B, Lopera-Mesa TM, Fairhurst RM, Tobon-Castaño A. 2017. Propeller Alleles, *mdr1* Polymorphism, and Drug Effectiveness at Day 3 after Artemether-Lumefantrine Treatment for *Plasmodium falciparum* Malaria in Colombia, 2014-2015. Antimicrob Agents Chemother 61, pii: e01036-17. <https://aac.asm.org/content/61/12/e01036-17>.
10. Kheang ST, Sovannaroeth S, Ek S, Chy S, Chhun P, Mao S, Nguon S, Lek DS, Menard D, Kak N. 2017. Prevalence of K13 mutation and Day-3 positive parasitaemia in artemisinin-resistant malaria endemic area of Cambodia: a cross-sectional study. Malar J 16:372. <https://doi.org/10.1186/s12936-017-2024-4>.
11. Cook J, Hergott D, Phiri W, Rivas MR, Bradley J, Segura L, Garcia G, Schwabe C, Kleinschmidt I. 2018. Trends in parasite prevalence following 13 years of malaria interventions on Bioko island, Equatorial Guinea: 2004-2016. Malar J 17:62. <https://doi.org/10.1186/s12936-018-2213-9>.
12. Kaur H, Allan EL, Mamadu I, Hall Z, Green MD, Swamidoss I, Dwivedi P, Culzoni MJ, Fernandez FM, Garcia G, Hergott D, Monti F. 2017. Prevalence of substandard and falsified artemisinin-based combination antimalarial medicines on Bioko Island, Equatorial Guinea. BMJ Glob Health 2:e000409. <http://dx.doi.org/10.1136/bmjgh-2017-000409>.
13. Li J, Chen J, Xie D, Eyi UM, Matesa RA, Ondo Obono MM, Ehapo CS, Yang L, Yang H, Lin M. 2016. Limited artemisinin resistance-associated polymorphisms in *Plasmodium falciparum* K13-propeller and PfATPase6 gene isolated from

- 357 Bioko Island, Equatorial Guinea. *Int J Parasitol Drugs Drug Resist* 6:54–59.
358 <https://doi.org/10.1016/j.ijpddr.2015.11.002>.
- 359 14. Chen JT, Li J, Zha GC, Huang G, Huang ZX, Xie DD, Zhou X, Mo HT, Eyi JUM,
360 Matesa RA, Obono MMO, Li S, Liu XZ, Lin M. 2018. Genetic diversity and
361 allele frequencies of *Plasmodium falciparum* msp1 and msp2 in parasite isolates
362 from Bioko Island, Equatorial Guinea. *Malar J* 17:458.
363 <https://doi.org/10.1186/s12936-018-2611-z>.
- 364 15. Wang SQ, Zhou HY, Li Z, Liu YB, Fu XF, Zhu JJ, Cao J, Gao Q. 2011.
365 Quantitative detection and species identification of human *Plasmodium spp.* by
366 using SYBR Green I based real-time PCR. *Zhongguo Xue Xi Chong Bing Fang*
367 *Zhi Za Zhi* 23:677–681.
- 368 16. Ogutu BR, Onyango KO, Koskei N, Omondi EK, Ongecha JM, Otieno GA,
369 Obonyo C, Otieno L, Eyase F, Johnson JD, Omollo R, Perkins DJ, Akhwale W,
370 Juma E. 2014. Efficacy and safety of artemether-lumefantrine and
371 dihydroartemisinin-piperaquine in the treatment of uncomplicated *Plasmodium*
372 *falciparum* malaria in Kenyan children aged less than five years: results of an
373 open-label, randomized, single-centre study. *Malar J* 13:33.
374 <https://doi.org/10.1186/1475-2875-13-33>.
- 375 17. Ursing J, Rombo L, Rodrigues A, Kofoed PE. 2016. Artemether-Lumefantrine
376 versus Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated
377 *Plasmodium falciparum* Malaria in Children Aged Less than 15 Years in
378 Guinea-Bissau - An Open-Label Non-Inferiority Randomised Clinical Trial. *PLoS*
379 *One* 11:e0161495. <https://doi.org/10.1371/journal.pone.0161495>.
- 380 18. Sow D, Ndiaye JL, Sylla K, Ba MS, Tine RC, Faye B, Pene M, Ndiaye M, Seck
381 A, Lo AC, Abiola A, Dieng Y, Gaye O. 2016. Evaluation of the efficacy and
382 safety of three 2-drug combinations for the treatment of uncomplicated
383 *Plasmodium falciparum* malaria in Senegal: artesunate-amodiaquine,
384 dihydroartemisinin-piperaquine, and artemether-lumefantrine. *Med Sante Trop*
385 26:45–50.
- 386 19. Wanzira H, Kakuru A, Arinaitwe E, Bigira V, Muhindo MK, Conrad M,
387 Rosenthal PJ, Kamya MR, Tappero JW, Dorsey G. 2014. Longitudinal outcomes
388 in a cohort of Ugandan children randomized to artemether-lumefantrine versus
389 dihydroartemisinin-piperaquine for the treatment of malaria. *Clin Infect Dis*
390 59:509–516. <https://doi.org/10.1093/cid/ciu353>.

20. Plucinski MM, Talundzic E, Morton L, Dimbu PR, Macaia AP, Fortes F, Goldman I, Lucchi N, Stennies G, MacArthur JR, Udhayakumar V. 2015. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uíge Provinces, angola. Antimicrob Agents Chemother 59:437–443. <https://doi.org/10.1093/cid/ciu353>.
21. Kakolwa MA, Mahende MK, Ishengoma DS, Mandara CI, Ngasala B, Kamugisha E, Kataraihya JB, Mandike R, Mkude S, Chacky F, Njau R, Premji Z, Lemnge MM, Warsame M, Menard D, Kabanywany AM. 2018. Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania. Malar J 17:369. <https://doi.org/10.1186/s12936-018-2524-x>.
22. Silva M, Ferreira PE, Otienoburu SD, Calçada C, Ngasala B, Björkman A, Mårtensson A, Gil JP, Veiga MI. 2019. *Plasmodium falciparum* K13 expression associated with parasite clearance during artemisinin-based combination therapy. J Antimicrob Chemother pii: dkz098. <https://doi.org/10.1093/jac/dkz098>.
23. WWARN K13 Genotype-Phenotype Study Group. 2019. Association of mutations in the *Plasmodium falciparum* Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments-a WWARN individual patient data meta-analysis. BMC Med 17:1. <https://doi.org/10.1186/s12916-018-1207-3>.
24. Baraka V, Tinto H, Valea I, Fitzhenry R, Delgado-Ratto C, Mbonye MK, Van Overmeir C, Rosanas-Urgell A, Van Geertruyden JP, D'Alessandro U, Erhart A. 2015. *In vivo* selection of *Plasmodium falciparum* Pfert and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother 59:734–737. <https://aac.asm.org/content/59/1/734>.
25. Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gnädig N, Uhlemann AC, Martin RE, Lehane AM, Fidock DA. 2016. Globally prevalent PfMDR1 mutations modulate *Plasmodium falciparum* susceptibility to artemisinin-based combination therapies. Nat Commun 7:11553. <https://www.nature.com/articles/ncomms11553>.
26. Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, Chy S, Kim S, Ke S, Kloeung N, Eam R, Khean C, Ken M, Loch K, Bouillon A, Domergue A, Ma L, Bouchier C, Leang R, Huy R, Nuel G, Barale JC, Legrand E, Ringwald P, Fidock DA, Mercereau-Puijalon O, Arieu F, Ménard D. 2017. A surrogate marker

- of piperaquine-resistant *Plasmodium falciparum* malaria: a phenotype-genotype association study. *Lancet Infect Dis* 17:174–183.
<https://linkinghub.elsevier.com/retrieve/pii/S1473309916304157>.
27. World Health Organization. 2000. Severe *falciparum* malaria. *Trans R Soc Trop Med Hyg* 94(Suppl 1):S1–S90.
28. Yao Y, Wu K, Xu M, Yang Y, Zhang Y, Yang W, Shang R, Du W, Tan H, Chen J, Lin M, Li J. 2018. Surveillance of Genetic Variations Associated with Antimalarial Resistance of *Plasmodium falciparum* Isolates from Returned Migrant Workers in Wuhan, Central China. *Antimicrob Agents Chemother* 62, pii: e02387-17. <https://aac.asm.org/content/62/9/e02387-17>.
29. Li J, Chen J, Xie D, Eyi UM, Matesa RA, Obono MMO, Ehapo CS, Yang L, Yang H, Lin M, Wu W, Wu K, Li S, Chen Z. 2015. Molecular mutation profile of Pfcrt and Pfmdr1 in *Plasmodium falciparum* isolates from Bioko Island, Equatorial Guinea. *Infect Genet Evol* 36:552–556.
<https://linkinghub.elsevier.com/retrieve/pii/S1567134815003627>.

Figure Legends

FIG 1 Primers and schematic representations of *K13* and *MDR1* nested PCR and sequencing strategies. New nested PCR and sequencing primers (A) were developed to capture the 7 MDR1 SNPs (B) and the whole K13 gene (C). The primers in the table are color-coded to match their positions in the schematics.

Table 1 Kelch13 and MDR1 polymorphisms of Bioko *P. falciparum* isolates in baseline population and D3-positively with DHA-PIP treatment

Polymorphisms	Baseline population, % (n=46)	D3, % (n=19)	Odds ratio (95 % CI)	p-value
<i>K13</i> gene				
H136N(CAT>AAT)	2 (4.3)	0 (0.0)	0.96 (0.90-1.02)	0.356
K189N(AAG>AAC)	18 (39.1)	7 (36.8)	1.06 (0.35-3.20)	0.863
K248N(AAG>AAT)	1 (2.2)	0 (0.0)	0.98 (0.94-1.02)	0.517
K326E(AAA>GAA)	1 (2.2)	0 (0.0)	0.98 (0.94-1.02)	0.517
K332N(AAA>AAC)	1 (2.2)	0 (0.0)	0.98 (0.94-1.02)	0.517
<i>MDR1</i> gene				
N86Y(AAC>TAT)	14 (30.4)	11 (57.9)	3.14 (1.04-9.50)	0.038*
Y184F(TAT>TTT)	31 (67.4)	17 (89.5)	4.11 (0.84-21.86)	0.065

*Baseline population: patients randomly selected from the 301 patients without ART-resistance, collected at D0; D3: the D3-positively patients after DHA-PIP treatment.

A.

	PCR or Sequencing Assay	Primer Sequence(5'-3')	Product	The Target Site
	Pf MDR1(1)-N1F	TTAAATGTTTACCTGCACAACATAGAAAATT	612bp	N86Y、E130K、Y184F
	Pf MDR1(1)-N1R	CTCCACAATAAATTGCAACAGTTCTTA		
	Pf MDR1(1)-N2F	TGTATGTGCTGTATTATCAGGA	526bp	
	Pf MDR1(1)-N2R	CTCTTCTATAATGGACATGGTA		
	Pf MDR1(2)-N1F	AATTTGATAGAAAAAGCTATTGATTATAA	880bp	S1034C、N1042D、 V1109I、D1246Y
	Pf MDR1(2)-N1R	TATTTGGTAATGATTTCGATAAATTCATC		
	Pf MDR1(2)-N2F	GAATTATTGTAAATGCAGCTTTA	799bp	
	Pf MDR1(2)-N2R	GCAGCAAACCTACTAACACG		
	Pf K13-PCR-F	CGGAGTGACCAAATCTGGGA	2097bp	F446I、N458Y、Y493H、 R539T、I543T、R561H、 C580Y
	Pf K13-PCR-R	GGGAATCTGGTGGTAACAGC		
	Pf K13-PCR-N1-F	GCCAAGCTGCCATTCATTTG	2027bp	
	Pf K13-PCR-N2-R	GCGGAAGTAGTAGCGAGAAT		

B.

C.